Recent preclinical studies demonstrated that selective inhibition of the proteolytic activity of MALT1 with small-molecule inhibitors blocks the anti-apoptotic NF-κB signaling pathway and elicits toxic effects selectively on MALT1-dependent subsets of ABC-DLBCL cells in vitro and in vivo with very little toxicity towards primary B cells [273, 274]. This evidence concerns the gene MALT1 and aneurysmal bone cyst.